Action MOLN MOLECULAR PARTNERS AG
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Molecular Partners AG

Actions

MOLN

CH0256379097

Temps réel estimé Cboe Europe
Autres places de cotation
 11:25:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
5,955 CHF +1,45 % Graphique intraday de Molecular Partners AG +0,84 % +74,42 %
20/06 Les plus fortes hausses du prémarché MT
17/06 Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
GL
Molecular Partners : Corporate Presentation - June 2024
PU
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
GL
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
GL
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
AQ
Molecular Partners : Corporate Presentation - June 2024
PU
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
AQ
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
GL
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
GL
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 
GL
Molecular Partners : Annual General Meeting Minutes
PU
Life Science Cares Launches in Switzerland
GL
Molecular Partners : statement regarding Passive Foreign Investment Company status
PU
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GL
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
AQ
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement
AQ
Molecular Partners Publishes Invitation to Annual General Meeting 2024
GL
Molecular Partners Publishes Invitation to Annual General Meeting 2024
AQ
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GL
Molecular Partners Announces Dismissal of Class Action Lawsuit
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MOLN
  4. Actualités Molecular Partners AG
  5. Communiqués